A study of TQB6411 for advanced esophageal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests an investigational drug called TQB6411 for people with advanced esophageal cancer that has worsened after prior treatment. The hope is that it may shrink tumors or slow the cancer's growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have recurrent or metastatic esophageal cancer that has been confirmed by biopsy or cytology.
- You have already tried and not been helped by a type of immunotherapy (PD-1/PD-L1 inhibitor) combined with chemotherapy.
- You are between 18 and 75 years old.
- You have a good performance status (able to be up and about more than half the day) and your doctors expect you to live longer than 12 weeks.
- You have at least one tumor that can be measured on a scan.
- Your blood counts, liver, and kidney function are within acceptable ranges (your doctor will check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called TQB6426 for people with advanced solid tumors that have not responded to other treatments. The drug targets a protein called GPC3 found on some tumors, aiming to deliver a powerful therapy directly to the cancer cells.
This trial tests a new combination of drugs (TQB2102, benmelstobart, and pembrolizumab) with or without chemotherapy for people with HER2-positive gastroesophageal cancer that cannot be removed by surgery or has spread. It aims to see if this combination is more effective than current treatments.
This trial tests a new drug, TQB6411, for people with advanced cancers that have not responded to standard treatments. It aims to see if the drug is safe and effective for different tumor types.
This trial tests a new drug called TQB6411 for people with lung cancer. It aims to see if the drug is safe and effective, and what side effects it might have.
This trial tests a new drug called TQB3142 in people with advanced cancers that have not responded to standard treatments. The goal is to find a safe dose and see how the drug works in the body.
This trial tests a new drug, TQB2922, for people with advanced cancers that have not responded to standard treatments. The goal is to see if it is safe and how it affects the cancer.
Hear when a new Esophageal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.